Navigation Links
Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
Date:8/22/2011

metastasis in adjuvant breast cancer.

XGEVA Regulatory Status

XGEVA has been approved in the U.S., Canada and the European Union (EU) for the prevention of SREs in patients with bone metastases from solid tumors.  XGEVA is not approved to prevent SREs in patients with multiple myeloma.

Amgen has also submitted marketing applications for XGEVA in Australia, Mexico, Russia and Switzerland. In Japan, Amgen is working with its licensing partner, Daiichi Sankyo Company, Limited and a marketing application was submitted. In addition, Amgen and GlaxoSmithKline (GSK) have a collaboration agreement for the commercialization of XGEVA in a number of countries where Amgen does not currently have a commercial presence. In these countries, marketing applications are filed by GSK.

XGEVA Important Safety Information

XGEVA can cause severe hypocalcemia. Correct pre-existing hypocalcemia prior to XGEVA treatment. Monitor calcium levels and administer calcium, magnesium and vitamin D as necessary. Advise patients to contact a healthcare professional for symptoms of hypocalcemia.

Osteocronosis of the jaw (ONJ) can occur in patients receiving XGEVA. Patients who are suspected of having or who develop ONJ while on XGEVA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

The most common adverse reactions in patients receiving XGEVA were fatigue/asthenia, hypophosphatemia and nausea. The most common serious adverse reaction in patients receiving XGEVA was dyspnea. The most common adverse reactions resulting in discontinuation of XGEVA were osteonecrosis and hypocalcemia. Please visit www.amgen.com or www.xgeva.com for full U.S. prescribing information.

Bone Metastases and SREs: Prevalence and Impact

Bone metastases occur in more than 1.5
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Acquire Exclusive Rights to Gastrin Based Therapies Program for ... ... TORONTO, March 13 Eli Lilly,and Company (NYSE: LLY ) ... two companies have entered into a licensing,and collaboration agreement granting Lilly ...
... KANSAS CITY, Mo., March 13 Synbiotics Corporation ... the Food & Drug,Administration (FDA) for the use ... in humans. This represents Synbiotics first foray into ... Synbiotics,initial intent to market this product itself to ...
Cached Medicine Technology:Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 2Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 3Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 4Synbiotics Corporation Announces Human Submission for FluDetect(R) 2
(Date:9/2/2015)... Boston, MA (PRWEB) , ... September 02, 2015 ... ... reports covering healthcare innovation and investment, announced the two leaders who will deliver ... Boston on November 3, at the Mandarin Oriental Hotel in Boston. , Larry ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and ... mixed documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps ... to reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... obesity being so much in the center of attention now ... cute, chubby babies might actually be too fat //for their ... crafted message that are coming from several top health groups, ... Control and Prevention and the American Academy of Pediatrics as ...
... to an outbreak of mosquito-borne encephalitis B in China, the ... to the 26 people already killed by the disease. ... infected with the disease and 40 of them have died ... in the first six months of 2006. But the newspaper ...
... a study published in the August issue of the Journal, ... have found //that certain risks factors put people younger than ... The findings were based on the study done on ... of people over 60. ,Peripheral vascular disease ...
... disclosed that a specific variety of adult ... neurons or other// types of tissue depending on the ... ,The researchers found that mesenchymal stem cells, which are ... clues from their local environment, allowing a transformation into ...
... exempting mental health units from the ban on smoking ... in the health of people// suffering mental ailments. Smoking ... premature death in the United Kingdom, with nearly 106,000 ... , ,The Health Act 2006 will make ...
... small study revealed that botox injections can help in healing ... Sherris, professor and chair of the department of otolaryngology at ... He said ” This is the first medication found to ... of Mayo Clinic Proceedings. ,The study was conducted ...
Cached Medicine News:Health News:Chubbiness In Babies Might Not Be A Cute Sign 2Health News:Adult stem cells are sensitive to responses from the environment 2Health News:Smoking Ban should Include Mental Health Units 2
Inquire...
... K2 / gel tubes are for ... molecular diagnostics and for viral load ... blood remain stable at room temperature ... optimal results, it is recommended to ...
Glass Whole Blood Tube with K3EDTA...
... transglutaminase (tTg) is a ubiquitous enzyme ... Tissue transglutaminase is also the specific ... endomysial antibody immunofluorescence (EMA) tests (Bio-Rad ... IgA and,IgG serologic tests are highly ...
Medicine Products: